TOMUDEX

This brand name is authorized in Australia, Austria, Canada, France, Malta, Spain, Turkey, UK.

Active ingredients

The drug TOMUDEX contains one active pharmaceutical ingredient (API):

1	Raltitrexed UNII 50VZN4BPUK - RALTITREXED DISODIUM
	Raltitrexed is a folate analogue belonging to the family of anti-metabolites and has potent inhibitory activity against the enzyme thymidylate synthase (TS). Compared to other antimetabolites such as 5-fluorouracil or methotrexate, raltitrexed acts as a direct and specific TS inhibitor. TS is a key enzyme in the de novo synthesis of thymidine triphosphate (TTP), a nucleotide required exclusively for deoxyribonucleic acid (DNA) synthesis. Inhibition of TS leads to DNA fragmentation and cell death.
	Read more about Raltitrexed

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TOMUDEX Powder for solution for infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BA03	Raltitrexed	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BA Folic acid analogues
Discover more medicines within L01BA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	4610P, 7256X
CA	Health Products and Food Branch	02229566
ES	Centro de información online de medicamentos de la AEMPS	61452
FR	Base de données publique des médicaments	60985360
GB	Medicines & Healthcare Products Regulatory Agency	73094
MT	Medicines Authority	AA505/10201
TR	İlaç ve Tıbbi Cihaz Kurumu	8699643790038